Please login to the form below

Not currently logged in
Email:
Password:

FTC

This page shows the latest FTC news and features for those working in and with pharma, biotech and healthcare.

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

The Federal Trade Commission (FTC) and Department of Justice (DoJ) said this week that they were implementing an expedited antitrust procedure to make it easier for companies to work together on

Latest news

  • Coronavirus disruption scuppers Curium Pharma sale Coronavirus disruption scuppers Curium Pharma sale

    AbbVie and Allergan signed a consent decree with the FTC this week covering the previously-announced divestments of inflammatory bowel disease drug brazikumab and two pancreatic replacement enzyme products, clearing a ... However the FTC has said it may

  • AbbVie says Allergan takeover delayed by FTC verdict AbbVie says Allergan takeover delayed by FTC verdict

    position. There’s no specified timeline for that review to complete, but AbbVie says it has “entered into a timing agreement with FTC staff that would likely result” in a ... The FTC asked for additional information from the two companies last

  • AbbVie/Allergan merger faces renewed public opposition despite divestments AbbVie/Allergan merger faces renewed public opposition despite divestments

    This is not the first public opposition to the AbbVie/Allergan merger – last September, the same groups urged the FTC to consider blocking the $63bn takeover. ... Given the hurdles Bristol-Myers Squibb and Celgene were required to jump over, it seems

  • AbbVie creates new aesthetics division amid Allergan takeover AbbVie creates new aesthetics division amid Allergan takeover

    In a letter to the FTC, the group presented concerns that the merger could lead to the combined AbbVie/Allergan company having too large of a market share in certain therapy ... The FTC has not shared any antitrust concerns, however, so it looks like the

  • Roche to close $4.3bn Spark deal after FTC clearance Roche to close $4.3bn Spark deal after FTC clearance

    The main concern posed by the CMA and the FTC is that the newly merged company could have an overly dominant position in the haemophilia A market. ... The FTC and CMA investigation into the merger was a surprise for not only Spark, but the entire pharma

More from news
Approximately 6 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    FTC. According to Michael A Carrier, a distinguished professor at Rutgers Law School, “the FTC has played a leading role in challenging ‘pay for delay’ settlements for two decades”. ... The FTC has also made legal arguments against the practice

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    In the US, the Federal Trade Commission (FTC) has followed a similar approach. ... The FTC challenged the merger, alleging harm to innovation and to future price competition.

  • Pharma deals in May 2015 Pharma deals in May 2015

    The product has been the subject of an investigation from the US Federal Trade Commission (FTC) and although not usually reported in Deal Watch, the $1.2bn settlement is noteworthy recognising ... This is not the first such case for Teva, as the FTC also

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics